Drug intelligence / Profile preview

Mitozin Discovery

Development stage: Preclinical
Lead developer: Metallomix
Modality: Small Molecules

Overview

Mitozin Discovery is a preclinical-stage drug candidate being developed by Metallomix for the treatment of mitochondrial dysfunction. It is an isotopically-modified compound based on stable zinc-64 (64Zn). The therapeutic is designed to repair mitochondrial function and restore cellular homeostasis through isotope-selective modulation, targeting pathways associated with oxidative stress and inflammation.

Beyond the preview

Go deeper on Mitozin Discovery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitozin Discovery.

Explore the full profile